Daniel C. Chan

6.5k citations

82 papers · 5.3k indexed · h-index 42

Impact in

Oncology top 2%
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
Toxicology top 1%

Papers in ⓘ

Toxicology 4
Oncology 31
- Peptidase Inhibition and Analysis 12
- HER2/EGFR in Cancer Research 6

Co-authors: Paul A. Bunn (33 shared papers)Rajesh Agarwal (9 shared papers)Rana P. Singh (6 shared papers)Chapla Agarwal (6 shared papers)Anil K. Tyagi (4 shared papers)Barbara A. Helfrich (15 shared papers)Dmitri B. Kirpotin (2 shared papers)Anna E. Barón (7 shared papers)
Journals: Clinical Cancer Research (6 papers)Cancer Research (5 papers)Canadian Journal of Physiology and Pharmacology (3 papers)Journal of Thoracic Oncology (2 papers)Lung Cancer (2 papers)
Partner nations: United States Japan China

In The Last Decade

Daniel C. Chan

81 papers receiving 5.1k citations

Peers

Countries citing papers authored by Daniel C. Chan

Since Specialization

Citations

This map shows the geographic impact of Daniel C. Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Chan more than expected).

Fields of papers citing papers by Daniel C. Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Chan. The network helps show where Daniel C. Chan may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel C. Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel C. Chan Line = papers co-authored together Daniel C. Chan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 82 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines Cancer Research ·Samir E. Witta, Robert M. Gemmill, Fred R. Hirsch, Christopher D. Coldren, Karla Hedman, Larisa Ravdel, Barbara A. Helfrich, Rafał Dziadziuszko, Daniel C. Chan, Michio Sugita, Chan Zeng, Anna E. Barón, Wilbur A. Franklin, Harry A. Drabkin, Luc Girard, Adi F. Gazdar, John D. Minna, Paul A. Bunn	2006	420
2	Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. PubMed ·Anil K. Tyagi, Rana P. Singh, Chapla Agarwal, Daniel C. Chan, Rajesh Agarwal	2002	283
3	Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth Circulation Research ·Shingo Ameshima, Heiko Golpon, Carlyne D. Cool, Daniel C. Chan, R. William Vandivier, Shyra J. Gardai, Marilee J. Wick, Raphael A. Nemenoff, Mark W. Geraci, Norbert F. Voelkel	2003	243
4	Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer Journal of Magnetism and Magnetic Materials ·Daniel C. Chan, Dmitri B. Kirpotin, Paul A. Bunn	1993	232
5	The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer Clinical Cancer Research ·David Raben, B. Helfrich, Daniel C. Chan, Fortunato Ciardiello, Limin Zhao, Wilbur A. Franklin, Anna E. Barón, Chan Zeng, Tim Johnson, Paul A. Bunn	2005	194
6	Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. PubMed ·Rana P. Singh, Sivanandhan Dhanalakshmi, Anil K. Tyagi, Daniel C. Chan, Chapla Agarwal, Rajesh Agarwal	2002	170
7	Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. PubMed ·Ariel Soriano, B. Helfrich, Daniel C. Chan, Lynn E. Heasley, Paul A. Bunn, Ting‐Chao Chou	1999	167
8	Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin C Lung Cancer ·Alvin M. Malkinson, David Siegel, Gerald L. Forrest, Adi F. Gazdar, Herbert K. Oie, Daniel C. Chan, Paul A. Bunn, M Mabry, D J Dykes, Steadman D. Harrison	1993	151
9	Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells Oncology Reports ·Akhilesh K. Tyagi, Chapla Agarwal, Daniel C. Chan, Rajesh Agarwal	2004	133
10	Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. PubMed ·Paul A. Bunn, B. Helfrich, Ariel Soriano, Wilbur A. Franklin, Marileila Varella‐Garcia, Fred R. Hirsch, Anna E. Barón, Chan Zeng, Daniel C. Chan	2001	131
11	Pim Family Kinases Enhance Tumor Growth of Prostate Cancer Cells Molecular Cancer Research ·Wei Wei Chen, Daniel C. Chan, Carlton D. Donald, Michelle M. Lilly, Andrew S. Kraft	2005	131
12	Peroxisome Proliferator-Activated Receptor-γ Is a Target of Nonsteroidal Anti-Inflammatory Drugs Mediating Cyclooxygenase-Independent Inhibition of Lung Cancer Cell Growth Molecular Pharmacology ·Marilee J. Wick, Greg Hurteau, Christina Dessev, Daniel C. Chan, Mark W. Geraci, Robert A. Winn, Lynn E. Heasley, Raphael A. Nemenoff	2002	125
13	Synergistic Anti-Cancer Effects of Grape Seed Extract and Conventional Cytotoxic Agent Doxorubicin Against Human Breast Carcinoma Cells Breast Cancer Research and Treatment ·Girish Sharma, Anil K. Tyagi, Rana P. Singh, Daniel C. Chan, Rajesh Agarwal	2004	124
14	Oral Silibinin Inhibits Lung Tumor Growth in Athymic Nude Mice and Forms a Novel Chemocombination with Doxorubicin Targeting Nuclear Factor κB–Mediated Inducible Chemoresistance Clinical Cancer Research ·Rana P. Singh, G. U. Mallikarjuna, Girish Sharma, Sivanandhan Dhanalakshmi, Anil K. Tyagi, Daniel C. Chan, Chapla Agarwal, Rajesh Agarwal	2004	114
15	Cross-talk between G Protein–Coupled Receptor and Epidermal Growth Factor Receptor Signaling Pathways Contributes to Growth and Invasion of Head and Neck Squamous Cell Carcinoma Cancer Research ·Sufi M. Thomas, Neil E. Bhola, Qing Zhang, Sarah Contrucci, Abbey L. Wentzel, Maria L. Freilino, William E. Gooding, Jill M. Siegfried, Daniel C. Chan, Jennifer R. Grandis	2006	112
16	Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels Clinical Cancer Research ·Barbara A. Helfrich, David Raben, Marileila Varella‐Garcia, Dan Gustafson, Daniel C. Chan, Lynne Bemis, Chris D. Coldren, Anna E. Barón, Chan Zeng, Wilbur A. Franklin, Fred R. Hirsch, Adi F. Gazdar, John D. Minna, Paul A. Bunn	2006	111
17	Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition Cancer Research ·Matias Casás‐Selves, Jihye Kim, Zhiyong Zhang, Barbara A. Helfrich, Dexiang Gao, Christopher C. Porter, Hannah A. Scarborough, Paul A. Bunn, Daniel C. Chan, Aik Choon Tan, James DeGregori	2012	109
18	Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC) Oncogene ·Yvette Bren‐Mattison, Vicki Van Putten, Daniel C. Chan, Robert A. Winn, Mark W. Geraci, Raphael A. Nemenoff	2004	105
19	Neuropeptides as Autocrine Growth Factors in Cancer Cells Current Pharmaceutical Design ·Terry W. Moody, Daniel C. Chan, Jan Fahrenkrug, Robert T. Jensen	2003	98
20	Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. PubMed ·Girish Sharma, Rana P. Singh, Daniel C. Chan, Rajesh Agarwal	2003	92

About Daniel C. Chan

Daniel C. Chan is a scholar working on Toxicology, Oncology, Genetics, Pharmacology and Molecular Biology, having authored 82 papers that have together received 5.3k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (12 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers), Lung Cancer Treatments and Mutations (9 papers), Cancer therapeutics and mechanisms (8 papers), Neuropeptides and Animal Physiology (8 papers), HER2/EGFR in Cancer Research (6 papers), Histone Deacetylase Inhibitors Research (6 papers) and Cancer-related gene regulation (6 papers). The work is most often cited by research in Oncology (1.6k citations), Toxicology (186 citations), Molecular Biology (3.0k citations), Pulmonary and Respiratory Medicine (1.4k citations) and Cancer Research (622 citations). Daniel C. Chan has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Paul A. Bunn, Rajesh Agarwal, Rana P. Singh, Chapla Agarwal, Anil K. Tyagi, Barbara A. Helfrich, Dmitri B. Kirpotin, Anna E. Barón, Wilbur A. Franklin and B. Helfrich. Their work appears in journals such as Clinical Cancer Research, Cancer Research, Canadian Journal of Physiology and Pharmacology, Journal of Thoracic Oncology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact